​

Ovid Therapeutics (OVID) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

OVID Stock Forecast

Ovid Therapeutics (OVID) stock forecast, based on 5 Wall Street analysts, predicts a 12-month average price target of $7.33, with a high of $11.00 and a low of $3.00. This represents a 890.54% increase from the last price of $0.74.

- $3 $6 $9 $12 $15 High: $11 Avg: $7.33 Low: $3 Last Closed Price: $0.74

OVID Stock Rating

Ovid Therapeutics stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 5 Strong Sell Sell Hold Buy Strong Buy

OVID Forecast vs Benchmarks

TypeNameUpside
StockOvid Therapeutics890.54%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts--3
Avg Price Target--$7.33
Last Closing Price$0.74$0.74$0.74
Upside/Downside--890.54%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 25152--8
Dec, 24152--8
Nov, 24252--9
Oct, 24352--10
Sep, 24452--11
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jul 02, 2024Raghuram SelvarajuH.C. Wainwright$3.00$0.86248.84%305.41%
May 20, 2024Thomas ShraderBTIG$11.00$3.14250.32%1386.49%
May 14, 2024Francois BriseboisOppenheimer$8.00$3.23147.68%981.08%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Jan 29, 2025OppenheimerPerformOutperformupgrade
Aug 19, 2024CitigroupUnderperformUnderperformhold
Jul 26, 2024H.C. WainwrightBuyBuyhold
Jun 18, 2024Cowen & Co.BuyBuyhold
Jun 18, 2024B. RileyBuyBuyhold
Jun 18, 2024H.C. WainwrightUnderperformUnderperformhold
Jun 18, 2024OppenheimerOutperformPerformdowngrade
Jun 18, 2024H.C. WainwrightBuyBuyhold
Jun 18, 2024BTIGBuyBuyhold
Jun 17, 2024CitigroupNeutralNeutralhold

Financial Forecast

EPS Forecast

$-5 $-2 $1 $4 $7 $10 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.38$1.78$-0.73$-0.74-----
Avg Forecast$-1.35$2.02$-0.75$-0.21$-0.47$-0.61$-0.34$-0.80$-0.80
High Forecast$-4.39$-0.36$-2.52$-0.57$-0.48$-0.78$-0.78$-0.98$-2.77
Low Forecast$0.24$6.56$0.14$0.14$-0.45$-0.15$0.47$-0.70$0.20
Surprise %2.22%-11.88%-2.67%252.38%-----

Revenue Forecast

$0 $120M $240M $360M $480M $600M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$12.62M$208.38M$1.50M$391.69M-----
Avg Forecast$11.08M$208.39M$1.47M$8.79M$662.78K$4.62M$26.61M$4.03M$21.59M
High Forecast$1.04M$19.61M$124.51K$8.28M$532.39K$174.91K$1.01M$152.46K$817.87K
Low Forecast$30.26M$569.19M$4.12M$9.54M$760.56K$13.29M$76.61M$11.59M$62.16M
Surprise %13.89%-0.00%2.42%4357.65%-----

Net Income Forecast

$-55B $-43B $-31B $-19B $-7B $5B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-80.73M$122.83M$-51.41M$-52.34B-----
Avg Forecast$-95.23M$142.45M$-53.11M$-14.94M$-32.50M$-42.71M$-28.91M$-59.29M$-56.70M
High Forecast$-309.56M$-25.31M$-177.97M$-40.06M$-33.64M$-54.98M$-55.10M$-69.17M$-195.18M
Low Forecast$16.92M$463.05M$10.07M$10.19M$-32.00M$-10.69M$32.91M$-49.41M$14.22M
Surprise %-15.22%-13.77%-3.20%350340.08%-----

OVID Forecast FAQ

Is Ovid Therapeutics stock a buy?

Ovid Therapeutics stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Ovid Therapeutics is a favorable investment for most analysts.

What is Ovid Therapeutics's price target?

Ovid Therapeutics's price target, set by 5 Wall Street analysts, averages $7.33 over the next 12 months. The price target range spans from $3 at the low end to $11 at the high end, suggesting a potential 890.54% change from the previous close price of $0.74.

How does Ovid Therapeutics stock forecast compare to the average forecast of its sector, industry, and investment themes?

Ovid Therapeutics stock forecast shows a 890.54% upside, outperforming the average forecast for the healthcare stocks sector (25.20%) and outperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for Ovid Therapeutics over the past three months?

  • January 2025: 12.50% Strong Buy, 62.50% Buy, 25.00% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 12.50% Strong Buy, 62.50% Buy, 25.00% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 22.22% Strong Buy, 55.56% Buy, 22.22% Hold, 0% Sell, 0% Strong Sell.

What is Ovid Therapeutics’s EPS forecast?

Ovid Therapeutics's average annual EPS forecast for its fiscal year ending in December is -0.47 for 2024, a -36.49% decrease from the reported $-0.74 in 2023. The prediction for 2025 is $-0.61, $-0.34 for 2026, $-0.8 for 2027, and $-0.8 for 2028.

What is Ovid Therapeutics’s revenue forecast?

Ovid Therapeutics's average annual revenue forecast for its fiscal year ending in December is $662.78K for 2024, a -99.83% decrease from the reported $391.7M in 2023. The forecast for 2025 is $4.62M, $26.61M for 2026, $4.02M for 2027, and $21.59M for 2028.

What is Ovid Therapeutics’s net income forecast?

For its fiscal year ending in December, Ovid Therapeutics's average annual net income forecast is $-32.502M for 2024, reflecting a -99.94% decrease from the reported $-52.339B in 2023. The projection for 2025 is $-42.705M, $-28.905M for 2026, $-59.288M for 2027, and $-56.7M for 2028.